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CASE PRESENTATION
A 53-year-old man was first evaluated in the outpa-
tient clinic of the American University of Beirut Medical
Center 2 years ago. He had been in good health until 13
years ago, when he developed leg swelling and “hyper-
tension and proteinuria”; records from that time were un-
available. The patient was living in Saudi Arabia. Renal
biopsy at that time revealed membranous nephropathy.
The serum creatinine was reported as “normal.” The pa-
tient reports being treated with the “Ponticelli protocol”
[1], with complete remission of symptoms.
The patient remained free of symptoms and without
treatment until 7 years ago, when swelling in his legs
returned while he was in Freiburg, Germany. A physi-
cian there performed a second renal biopsy, which con-
tained 17 glomeruli, none of which was sclerosed, and all
of which demonstrated typical light and electron micro-
scopic features of membranous nephropathy. The urinary
protein excretion (Upr) was 20 g/24 hours, and the serum
creatinine was 1.2 mg/dL. Blood pressure was 140/100
mm Hg. Between 7 and 2 years ago, the patient received
treatment with mycophenolate mofetil (CellCept) for 4
years, a repeat of the “Ponticelli protocol,” and, when
seen by us 2 years ago, he was receiving cyclosporine A
(175 mg/day). Steroids had been discontinued because
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the patient had a severe psychosis characterized by ag-
gressive behavior and other untoward effects, including
skin changes and osteoporosis of the spine. His serum
creatinine also had risen gradually, to 1.4 mg/dL 3 years
ago, and was 1.9 mg/dL when we examined him 2 years
ago. The Upr had fluctuated markedly between 7 and
2 years ago, with a maximal value of 14 g/24 hours 3 years
ago.
Two years ago, his Upr was 1.74 g/24 hours and his
blood pressure was 130/90 mm Hg. The rest of the phys-
ical examination was unremarkable. His medications in-
cluded (in addition to cyclosporine), enalapril (10 mg
twice a day), hydrochlorothiazide (25 mg/day), and ator-
vastatin (20 mg/day). No changes in therapy were advised,
and he was asked to return for follow-up in 2 months. He
was not seen until 7 months later, at which time his serum
creatinine was 2.0 mg/dL, Upr was 1.72 g/24 hours, and the
blood pressure had increased to 160/110 mm Hg. Losar-
tan was added at 100 mg/day. Between February and De-
cember of last year, cyclosporine A was continued but
at a lower dose, and marked improvement was noted in
the Upr, which fell to 0.19 g/24 hours; his blood pressure
was lower than 130/80 mm Hg. The serum creatinine was
stable at 1.9 to 2.0 mg/dL.
The patient was lost to follow-up until 3 months ago,
when he was again seen in clinic for elevated blood
pressure (150/100 mm Hg), increased serum creatinine
(2.4 mg/dL), and increased Upr (1.5 g/24 hours). Over the
subsequent 2 weeks, serum creatinine increased rapidly
to 4.4 mg/dL and Upr to 4.3 g/24 hours. Tissue from
a third renal biopsy performed last month contained
12 glomeruli, three of which were sclerosed. The re-
mainder were characterized by advanced membranous
nephropathy on electron microscopy, but severe prolif-
erative changes also were present in all glomeruli, with
crescent formation in three of them. In seven glomeruli,
trichrome stain revealed moderate to advanced fibrotic
changes. Titers for anti-glomerular basement membrane
(anti-GBM) antibodies were positive. The patient was ad-
mitted to the hospital for intravenous cyclophosphamide
therapy and plasmapheresis; therapy reduced his serum
creatinine to 2.8 mg/dL. He is still under close monitoring
for active proliferative glomerulonephritis complicating
underlying, long-standing membranous nephropathy.
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DISCUSSION
DR. KAMAL F. BADR (Professor and Chair, Depart-
ment of Internal Medicine, Attending Nephrologist, Amer-
ican University of Beirut Medical Center, American Uni-
versity of Beirut, Beirut, Lebanon): “This book is written
because we have come to the conclusion that the present
day treatment of patients with renal [glomerular] disease
is inadequate and sometimes dangerous.” Thomas Addis
in Glomerular Nephritis, 1948.
Fifty-six years of clinical and basic research later, Ad-
dis’s statement remains valid, and the clinical course of
this patient reflects the reasons: we still have no definitive
therapy for one of the most common forms of glomeru-
lar disease in adults, membranous nephropathy [2]. It
also reflects our poor understanding of the factors that
govern the natural progression (or lack thereof) of this
disease, the frustrations and complications of the various
immunosuppressive therapies, and the lack of substantial
decisive evidence favoring a particular course of treat-
ment over another in a given patient. In the case of this pa-
tient, whose professional life entails moving among sev-
eral locations (Saudi Arabia, Germany, and Lebanon),
this created even greater confusion, since caregivers have
no clear internationally recognized treatment guidelines.
The lack of consensus on therapy for glomerulonephri-
tis is by no means unique to membranous nephropa-
thy. Equally frustrating to physicians and patients is the
management of IgA nephropathy, primary proliferative
glomerulonephritides, membranoproliferative glomeru-
lonephritis, and many subtypes of lupus nephritis and
other secondary forms of glomerulonephritis [2]. Ap-
proximately 1.0 to 1.5 million individuals worldwide carry
the diagnosis of glomerulonephritis [3]. Primary and sec-
ondary glomerulonephritis are identified as the under-
lying cause of end-stage renal disease in 15% to 20%
of patients currently undergoing dialysis in the United
States [3]. This percentage has remained relatively con-
stant over the past 25 years despite the steadily increasing
total number of dialysis patients; this supports the notion
that, since the days of Addis, we have failed to achieve
significant progress in treating glomerulonephritis [3].
In all forms of glomerulonephritis, the only avail-
able treatments today are immunosuppressive agents
(Table 1), the use of which is associated with numerous
complications and untoward effects, including nephro-
toxicity with agents such as cyclosporine (as in this
patient). In this Forum, I aim to address the reasons un-
derlying the disappointing lack of progress in affecting
the course of glomerulonephritis despite several decades
of research into the pathophysiology and therapy of these
diseases. I shall address these questions based on the
fundamental principle that our aim as nephrologists is
primarily to arrest or reverse the two major functional
morbidities associated with glomerulonephritis: protein-
uria and renal insufficiency [reduction in glomerular fil-
tration rate (GFR)]. I will attempt to answer six ques-
tions: (1) What is glomerulonephritis? (2) How does
glomerulonephritis lead to proteinuria? (3) What are
treatment strategies for proteinuria in glomerulonephri-
tis? (4) How does glomerulonephritis lead to reduced
GFR? (5) What are treatment strategies for preserving
GFR in glomerulonephritis? (6) Is renal biopsy helpful
in determining treatment outcomes?
What is glomerulonephritis?
A clear definition of glomerulonephritis is warranted
for the purpose of this discussion because several forms
of glomerular disease associated with proteinuria and
progressive renal insufficiency, such as focal segmental
glomerulosclerosis, are often labeled as glomerulonephri-
tis, when in fact little or no inflammatory reaction is
identified on biopsy. The term “glomerulonephritis”
is therefore restricted to diseases in which glomeruli
contain inflammatory cells, namely, polymorphonuclear
leukocytes (PMNs), tissue macrophages, or lymphocytes,
beyond the number expected in normal glomeruli (“res-
ident” macrophages) [4]. In the vast majority, immune
deposits (antigen-antibody complexes) are demonstrable
in mesangial, subendothelial, or subepithelial locations
in affected glomeruli [2]. In some cases, such as mem-
branous nephropathy, inflammatory changes cannot al-
ways be readily identified on routine light microscopy.
Careful analysis of glomeruli from such patients, how-
ever, clearly identifies increased numbers of activated
glomerular macrophages [5, 6]. The presence of infil-
trating leukocytes is usually a result of chemoattractant
stimuli, predominantly the C5a component of comple-
ment [2, 5, 6] and leukotriene B4 [7] which, in turn,
are released following antigen-antibody complex depo-
sition and the initial wave of PMN infiltration within
the glomerulus [2, 5–7]. Thus, glomerulonephritis is es-
sentially an auto-destructive inflammatory disease, much
like auto-immune arthritis, vasculitis, or colitis. This be-
ing the case, does the fact that the patient was diagosed as
having “membranous” glomerulonephritis provide addi-
tional useful information for prognosis or therapy?
As Figure 1 illustrates, auto-immune antibody–
mediated glomerulonephritis can be viewed conceptu-
ally as consisting of three distinct phases: initiation, am-
plification, and effector cell activation (which mediates
functional deterioration). In the first phase, the “spark”
that initiates the reaction must occur. In membranous
glomerulopathy, this consists of antibody binding to anti-
gen on the glomerular epithelial cell [2, 5], but it could
be any of a number of other sites or routes of immune
complex deposition (see Fig. 1). In some cases, such
as acute post-infectious glomerulonephritis or experi-
mental anti-GBM antibody-mediated injury, antibody
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Table 1. Currently available therapies for glomerulonephritis
Disease Immunosuppressive therapy Other therapy
Membranous glomerulonephritis Corticosteroids, cyclophosphamide, azathioprine,
cyclosporine A, mycophenolate mofetil, anti-C5
antibodies, anti-B cell antibody (rifuximab)
Intravenous Ig
Mesangial proliferative
glomerulonephritis
Corticosteroids, cyclophosphamide Dipyridamole, aspirin, warfarin
IgA nephropathy Corticosteroids, cyclophosphamide, cyclosporine A,
azathioprine, mycophenolate mofetil
Intravenous Ig, angiotensin-converting
enzyme inhibitors, angiotensin receptor
blockers, fish oil
Crescentic glomerulonephritis Corticosteroids Plasmapheresis
Anti-glomerular basement membrane
glomerulonephritis
Corticosteroids, cyclophosphamide, cyclosporine A,
azathioprine
Plasmapheresis
Pauci-immune crescentic
glomerulonephritis
Corticosteroids, cyclophosphamide, azathioprine
Lupus glomerulonephritis Corticosteroids, cyclophosphamide mycophenolate
mofetil, azathioprine, cyclosporine,
tolerance-inducing molecules (LJP-394), lymphoid
irradiation, stem cell transplant
Intravenous Ig, thromboxane A2 antagonist
Wegener’s vasculitis Corticosteroids, cyclophosphamide, mycophenolate
mofetil, cyclosporine A
Plasmapheresis
Polyarteritis Corticosteroids, cyclophosphamide
binding leads to an acute PMN infiltrate that imme-
diately mediates functional deterioration (proteinuria,
decreased GFR) [2, 7–10]. In the majority of clinically
encountered glomerulonephritides, however, acute PMN
infiltration is not apparent on renal biopsy. Rather, a
chronic reaction is set in motion (amplification) in which
complement components, T cells, cytokines, autacoids,
lipid mediators, and other biologically active molecules
secreted by indigenous and infiltrating cells participate
to various degrees in antigen recognition and amplifica-
tion as well as perpetuation of the initial insult [2]. As
Figure 1 shows, activation of indigenous glomerular cells,
infiltrating leukocytes, and platelets mediates the func-
tional consequences that underlie clinical disease. The ex-
tent of proteinuria and the magnitude and the time course
of reduction in GFR are highly variable, not only among
the various pathologic classifications of glomerulonephri-
tis, but also among individual patients within each disease
category [2].
Our current “naming” (classification) of glomeru-
lonephritis into the various pathologic entities recog-
nized in clinical nephrology is based on unrelated and
seemingly random parameters, which include: the site
of immune-complex deposition and cellular prolifera-
tion (“mesangioproliferative” glomerulonephritis), de-
scriptive pathology of affected structures (“membranous,”
or “membranoproliferative,” indicating basement mem-
brane thickening with or without cellular prolifera-
tion, respectively), the ultrastructural target of circulat-
ing antibodies (“anti-GBM” disease), the type of reactive
antibody (“IgA nephropathy”), the underlying systemic
disease (“lupus nephritis”), or the predominant anatomic
distribution of inflammatory changes (“focal segmental
glomerulonephritis”). The lack of significant progress in
our treatment of glomerulonephritis using these defini-
tions of disease can be attributed, in part, to the lack
of any specific and reproducible clinical implications for
these definitions of disease. Are these pathologic expres-
sions of glomerulonephritis sufficiently distinct in their
clinical outcomes to warrant their classification as sep-
arate disease entities, or are they merely a reflection of
variability in the permutations of immune-complex for-
mation and localization against the complex structural
background of the glomerulus? In almost all these disease
entities, clinical outcome is determined not by the name
we give to the inflammatory process, but by the severity
and the time course of injury, both of which are extremely
variable and unpredictable, as illustrated in “membra-
nous” or “IgA” nephropathies. After so many years and
so little progress [3], is it time to question the validity,
utility, and clinical relevance of paradigms which are, in
essence, descriptive pathologic variations on the mono-
tone theme of auto-immune inflammation (in a complex
micro-anatomy) translated, without sufficient justifica-
tion, into distinct clinical entities?
How does glomerulonephritis lead to proteinuria?
Proteinuria is a feature of all forms of glomerulonephri-
tis. In fact, proteinuria is a feature of almost any glomeru-
lar disease, whether inflammatory or not. We now
realize that the reason for this lies in the exquisitely
sensitive predisposition of the glomerular podocyte to
injury, and the vital role of structural and functional
integrity of the podocyte in preserving the permselec-
tivity of the filtration barrier to the passage of albu-
min and macromolecules [11–30]. In particular, it is now
clear that the slit diaphragm, which connects podocyte
foot processes to each other as they overlay the base-
ment membrane, is the principal locale of fluid flux into
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Fig. 1. The pathophysiology of proteinuria and of decreased glomerular filtration rate (GFR) during glomerulonephritis. Podocyte injury results
from direct complement binding and from activation (∗) of glomerular and infiltrating cells, leading to proteinuria, the magnitude of which is amplified
by elevations in single nephron plasma flow rates (QA) and glomerular capillary pressure (PGC). The fall in GFR is attributed to reductions in the
filtering surface area (and possibly other) components of the glomerular capillary ultrafiltration coefficient (Kf), which can result from reversible
mesangial cell (MC) contraction, irreversible structural damage, or a combination of both. Abbreviations are: ROS, reactive oxygen species; TxA2,
thromboxane A2; GFs, growth factors; NO, nitric oxide; GEN, glomerular endothelial cells; PMN, polymorphonuclear cells; MPh, macrophages;
IC, immune complex; GBM, glomerular basement membrane.
Bowman’s space. Injury, dysregulated function, or ac-
tivation of surface receptors of the podocyte, its foot
processes or slit diaphragm molecular composition, re-
sults in proteinuria and nephrotic syndrome in several
forms of congenital and acquired proteinuric disorders
[11–37]. Several excellent recent reviews describe the
rapid increase in our body of knowledge on the biology
and pathobiology of the glomerular podocyte, its genetic
development, molecular equipment, anatomic organiza-
tion, and role in proteinuric disorders [11–13, 23]. A sum-
mary of slit diaphragm and podocyte-associated proteins
that have been implicated in mediating congenital and
acquired nephrotic syndrome and/or proteinuria is pre-
sented in Figure 2. Judging by the exponentially expand-
ing literature on the podocyte, we can expect many more
years of effort and an increasing number of publications
devoted to this fascinating cell.
Appreciation of the central role of the podocyte and
the slit diaphragm in glomerular molecular sieving func-
tion inevitably led to its study in the context of glomeru-
lar inflammation. In the particular case of membranous
nephropathy and its experimental models (active and
passive Heymann nephritis), the podocyte itself is the tar-
get of the antibodies that initiate the process of glomeru-
lar inflammation [2, 4–6]. The target antigen is localized
to the foot processes, to which antibodies gain access
through as-yet-incompletely defined pathways [2]. The
binding of antibody to podocyte cell membrane, the re-
sulting activation of complement, and the subsequent
inflammatory reaction and macrophage activation all
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Fig. 2. Podocyte injury in glomerulonephritis. Summary of the current literature on established complement and cell activation-dependent me-
diators of podocyte injury and target proteins on the podocyte and the slit diaphragm which have been associated with congenital or acquired
proteinuria [11–33]. Note that mechanical stress imposed by elevations in single nephron plasma flow rate (QA) and glomerular capillary pressure
(PGC) results from vasoactive locally released products of cellular activation [4–10], as well as the adaptive responses to progressive nephron loss.
See Figure 1 and text for abbreviations.
conspire to disrupt podocyte integrity and produce mas-
sive proteinuria [2, 4–6, 18, 24, 29]. In approximately 10%
of patients, long-standing smoldering inflammation can
increase in severity with the development of anti-GBM
disease, as occurred in the patient described here, and can
lead to rapid deterioration in GFR and robust inflamma-
tory changes on biopsy (including “crescent” formation)
[2]. In all other forms of glomerulonephritis, podocyte
injury and proteinuria result from the consequences of
inflammatory reactions occurring in the vicinity of the
podocyte or even in the mesangium [11–13]. Two princi-
pal pathways have been described as mediating podocyte
injury during acute and chronic glomerulonephritis:
direct attack by complement (particularly the C5b-9
complex) or, more significantly in the chronic phase of in-
jury, disruption of podocyte functions by autacoids of the
inflammatory response released following activation of
PMNs, macrophages, mononuclear cells, and indigenous
glomerular cells [11–37] (Fig. 1). The latter pathway in-
volves numerous classes of biologically active molecules
including reactive oxygen radicals [11], proteases [12, 13],
leukotrienes, thromboxane and other vasoactive lipids [5,
38, 39], cytokines [31–33], growth factors [30], nitric oxide
[26, 27, 34], and others [35]. In several cases, these locally
generated mediators have been linked to specific molec-
ular targets within or on the surface of podocytes [11–
13] (Fig. 2). Taken together, these observations provide
intriguing insight into the multiple mechanisms of pro-
teinuria in various forms of inflammatory injury in the
glomerulus but provide little hope for specific targeted
interventions. It is clear from the totality of podocyte-
focused research that, in the control of glomerular macro-
molecular sieving, foot processes and slit diaphragms
bear an exquisitely delicate anatomic and functional
1910 Nephrology Forum: Filtration function in glomerulonephritis
relationship to the underlying basement membrane, and
that even subtle abnormalities in the micro-environment
can affect these relationships in a manner that invariably
seems to cause loss of the normal restriction to albumin
filtration [11–37]. That the GFR is normally close to 180
liters/day results in dramatic amplification of abnormal
single-nephron sieving function and leads to overt pro-
teinuria.
Acute elevation of glomerular capillary pressure in the
normal glomerulus does not produce significant protein-
uria but will do so when sustained for prolonged peri-
ods (hyperfiltration nephropathy) [40]. In the presence
of glomerular inflammatory injury, however, lowering
of intraglomerular pressure often is associated with sig-
nificant amelioration of proteinuria. This decrease sug-
gests that in the presence of pre-existing pathology in
podocyte structure or function, elevated (or even nor-
mal) glomerular pressure exacerbates abnormal protein
passage [2]. In addition to elevated capillary pressure,
proteinuria can be exacerbated by diminished rates of
single-nephron plasma filtration rates, likely as a result
of prolonged contact time and diffusion-governed trans-
membrane protein passage [41]. In experimental mod-
els of chronic glomerulonephritis, single-nephron plasma
flow rates (QA), glomerular capillary pressure (PGC),
and net transcapillary hydraulic pressure difference (P)
were elevated [5, 8–10, 39, 42], in keeping with clinical
observations [43, 44]. Increased single-nephron pressure
and flow might represent significant mechanical stress
to glomerular mesangial and epithelial cells (podocytes);
this stress, in turn, is associated with secondary patho-
logic alterations in these cells [11, 45], further exacerbat-
ing proteinuria and nephron loss (Figs. 1 and 2).
What are treatment strategies for proteinuria in
glomerulonephritis?
Glomerulonephritis has received little attention from
the pharmaceutical industry as a distinct target for re-
search and drug development. This is not surprising, as
the “market size” for these diseases worldwide is compar-
atively small, and their pathophysiology complex. Ther-
apeutic tools available to the nephrologists are entirely
“borrowed” from other disciplines and mainly comprise
immunosuppressive agents, of which corticosteroids con-
tinue to be the most commonly used (Table 1).
As I said earlier, proteinuria during glomerular inflam-
mation is a result of direct complement-mediated and/or
inflammation-associated podocyte injury. Complement
components and products of inflammation collectively
target a multiplicity of cell surface, slit-diaphragm, and
intracellular podocyte structures (Fig. 2). It is therefore
unlikely that a single anti-proteinuric agent aimed at any
of the myriad potential targets of injury on podocytes will
prove useful in completely abrogating proteinuria dur-
ing glomerulonephritis. Thus, at present, the treatment
of proteinuria in patients with active glomerulonephri-
tis primarily depends on the control of inflammatory
injury through the use of immunosuppressive agents.
Some additional tools are in various stages of valida-
tion as effective interventions for reducing proteinuria
in human glomerulonephritis: angiotensin antagonists,
complement antagonists, and 5-lipoxygenase-activating
protein antagonists.
In keeping with the notion that elevated intracap-
illary pressure in the glomerulus exacerbates protein-
uria, success in reducing urinary protein excretion in
glomerulonephritis has been achieved through the use of
angiotensin antagonist therapy, including protocols com-
bining angiotensin-converting-enzyme (ACE) inhibitors
(ACEi)s and angiotensin receptor blockers (ARBs)
[2]. In fact, prolonged use of intensive angiotensin
antagonism has been associated with improved prog-
nosis in some forms of glomerulonephritis (such as
IgA nephropathy) [2]. Proteinuria in and of itself
is considered of pathologic significance in mediating
downstream (tubule) tissue damage, so it is possible that
intensive combined (ACEi and ARB) angiotensin antag-
onism therapy will prove increasingly effective in the pre-
vention of disease progression.
Complement-neutralizing antibodies (anti-C5 anti-
bodies) have been developed for human use in attempts
to limit infarct size during acute myocardial infarction
[46, 47]. Such therapies, however, have not been tested in
human glomerulonephritis.
Biologically active products of the 5-lipoxygenase
pathway of arachidonic acid metabolism have been im-
plicated in mediating proteinuria and reductions in GFR
in several forms of experimental glomerulonephritis [5,
7, 8; reviewed in 39, 48–50]. In the first trials in human
disease, 11 patients with active glomerulonephritis were
treated for 4 days with twice-daily doses of an orally active
antagonist of 5-lipoxygenase activating protein (FLAP),
MK-591, a key nuclear membrane-bound protein re-
quired for 5-lipoxygenase activation and leukotriene syn-
thesis [51]. Short-term therapy with MK-591 reduced
proteinuria in these patients by 50% without altering sys-
temic hemodynamics, GFR, or renal plasma flow rates.
Analysis of the fractional clearance of polydispersed dex-
trans revealed that treatment with MK-591 caused a
selective improvement in the passage of large (≥50 A˚)
dextrans without affecting the handling of smaller dex-
trans, indicating an improvement in glomerular size se-
lectivity [51].
How does glomerulonephritis reduce GFR?
Progressive reduction in the GFR is the most serious
consequence of chronic glomerulonephritis. In membra-
nous nephropathy as well as in IgA nephropathy, lupus
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Fig. 3. (A) Individual glomeruli in patients with glomerulonephritis fall into one of four histopathologic patterns: normal, inflammation without
fibrosis, a combination of inflammation and fibrosis in the same glomerulus, and fibrosis with loss of architectural integrity. (B) The rates at which
glomerular filtration rate (GFR) is lost can vary infinitely and are described by a family of curves (r1 to rn). A 50% reduction in GFR, however,
may result solely from reversible reductions in Kf (A), irreversible reductions in Kf (C), or a combination of both (B) (See Fig. 2). (C) Dynamic
evolution of the principal mechanism underlying the fall in total GFR over the course of glomerular inflammatory injury as individual glomeruli
transition from stage II to stage IV. Essential to the choice of therapy (anti-inflammatory, anti-fibrotic, or none) is valid quantitative measurements
of the proportion of nephrons in each stage (see hypothetical profiles described in text). ESRD is end-stage renal disease; SNGFR is single-nephron
GFR.
nephritis, and all other forms of classically recognized
histopathologic disease entities, patients can survive for
years with relative preservation of GFR, can experience
a slow progressive reduction in GFR, or can lose renal
function rapidly over the course of days to weeks [2]
(Fig. 3B). So far, few specific prognostic indexes can reli-
ably predict the course of renal functional deterioration
in any of the various nephritides. In addition to inter-
individual variability, single-nephron GFR (SNGFR)
varies widely among nephrons in each patient, as evi-
denced by the extreme variability in histologic involve-
ment of nephron units on biopsy (Fig. 3A). Estimation of
GFR from serum creatinine reflects overall integration
of nephron function and does not provide information as
to the underlying mechanism.
Clearly, GFR is compromised by the presence of in-
flammation in the glomerulus. In rats fed an arachidonic
acid–deficient diet from the time of weaning until adult-
hood, immune-complex deposition fails to elicit a cellular
response, and glomerular functions (including GFR) are
completely preserved [52]. These observations support
a significant body of evidence that assigns central roles
for cyclo-oxygenase and lipoxygenase products of arachi-
donic acid in sustaining and perpetuating histopathologic
and functional alterations in glomerulonephritis [5, 7, 8,
38, 39, 48–51]. Studies using glomerular micropuncture
have defined the mechanisms underlying the fall in GFR
during acute inflammation as being primarily a reduction
in the glomerular capillary ultrafiltration coefficient (Kf)
[4–10, 38, 39]. The determinants of Kf are the glomeru-
lar transcapillary hydraulic permeability (k) and the cap-
illary surface area available for filtration (S) [53]. The
latter is in turn a reflection of two components: struc-
turally intact glomerular architecture (that is, absence of
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fibrosis, collapse, or disruption of structure-function re-
lationships between capillaries and corresponding Bow-
man space), and the state of contraction or relaxation of
mesangial cells, which determines the number of open
capillary loops in a particular glomerular tuft [53]. Loss
of structure is associated with irreversible loss of surface
area, whereas mesangial cell contraction is potentially
reversible [8] (see Fig. 1). These formulations represent
a simplified approach to explaining the fall in Kf during
glomerulonephritis; the exact mechanisms could be more
complex. As-yet poorly understood factors (other than
structural damage and reduction of open capillary loops)
could underlie the fall in Kf and might be reversible with
anti-inflammatory therapy [14]. Thus, in a particular pa-
tient, reduced SNGFR in all involved glomeruli might
reduce overall GFR but maintain an intact complement
of nephrons (as in acute post-infectious glomerulonephri-
tis). More commonly, a combination of reversible reduc-
tions in SNGFR in some nephrons and an irreversible loss
of filtration surface area due to disruption/destruction of
structural elements in other nephrons together decrease
GFR (Fig. 3).
Reversibility of the fall in GFR during acute glomeru-
lonephritis is a crucial determinant of the indications
for immunosuppressive therapy. As Figure 3 illustrates,
the success of therapy in preserving GFR in unaffected
glomeruli, or in reversing the reduction in SNGFR in
inflamed but as-yet non-fibrosed glomeruli, can only be
accurately predicted if the percent contribution of the
functional (reversible) fall in Kf to the overall reduction
in GFR is known. At present, we assign, based on ex-
amination of renal biopsy, what is known as an “activ-
ity versus chronicity score,” to determine reversibility of
the fall in GFR. Based on this “measurement,” the clini-
cian decides on the administration, or the withholding, of
immunosuppressive therapy [2, 54]. In my discussion of
treatment strategies for the fall in GFR, I shall argue that
this approach does not in fact provide a faithful or a repro-
ducible reflection of the extent of reversibility of the loss
of filtration function. Without a reliable estimate of the
contribution of inflammation versus fibrosis to the overall
loss of GFR, the outcomes of therapeutic interventions
cannot be judged.
What are treatment strategies for preserving GFR
in glomerulonephritis?
In the patient presented here, who carried the diagno-
sis of membranous nephropathy for 18 years, GFR was
initially preserved, but gradual loss of renal function en-
sued in the latter part of his disease as the serum crea-
tinine level rose to 1.4 and then 2.0 mg/dL. In the latest
phase of his disease, the GFR was reduced markedly and
rapidly, as his glomerular lesion transformed into a severe
proliferative form of glomerulonephritis. The impact of
immunosuppressive treatment on GFR was difficult to
evaluate in the chronic phase of the disease, but intra-
venous cyclophosphamide (and possibly plasmaphere-
sis) were clearly associated with rapid improvement in
GFR following transformation of the lesion to a prolif-
erative crescentic glomerulonephritis. Acute substantial
improvements in GFR by the use of pulse steroids, intra-
venous cyclophosphamide, or other measures in patients
with acute or subacute proliferative glomerulonephritis
illustrate that a significant portion of the fall in GFR is
due to reversible reductions in Kf, mediated by locally
released vasoactive and cytotoxic products of the inflam-
matory reaction. In experimental models of glomerular
injury, a wide range of mediators have been implicated
as underlying the fall in Kf during glomerular inflamma-
tion [4–10, 14, 26, 38, 39, 42–44, 48–52, 55]. At present,
however, the only available clinical therapeutic tools are
drugs that non-specifically reduce the number or acti-
vation status of inflammatory leukocytes and/or indige-
nous glomerular cells (Table 1). Whereas immunosup-
pressive (and potentially anti-complement) therapies aim
at arresting injury and restoring GFR by reversing re-
ductions in SNGFR in glomeruli with “active” lesions,
therapies targeting glomerular fibrosis might become
available in the future, such as agents aimed at neu-
tralizing the biologic actions of vascular endothelial
growth factor (VEGF) [56]. Additionally, intriguing re-
sults in experimental animals suggest that “high-dose”
angiotensin antagonist therapy might reduce and reverse
matrix deposition and fibrosis [57]. Future choices among
anti-inflammatory versus anti-fibrotic therapies for pre-
serving GFR during glomerulonephritis, however, would
still require a reliable profiling of nephronal distribution
of “activity versus chronicity.”
Is renal biopsy helpful in determining treatment
outcomes?
At first glance, it might seem reasonable to assume
that, because glomerulonephritis involves nephrons in
a random fashion, a random sample, no matter its size,
should reflect the true distribution of active versus fibrotic
glomeruli in a particular patient. The margin of error,
however (that is, the deviation of the estimated propor-
tion of normal, proliferative, partially fibrotic, and glob-
ally fibrotic glomeruli from the true distribution of these
categories in the total nephron population) increases as
the sample number decreases, and thus is unacceptably
high for the number of glomeruli usually obtained on
routine renal biopsy (Table 2).
Let us consider two hypothetical patients (A and B)
with membranoproliferative glomerulonephritis. Both
present with similar clinical findings of active urinary sed-
iment, hypertension, proteinuria, and azotemia (serum
creatinine, 3.5 mg/dL). Patient A has sustained severe
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Table 2. Margins of error for 90% to 99% confidence intervalsa
Confidence
Sample 90% 95% 98% 99%
A
10 22.59 26.84 31.90 35.33
20 15.98 18.98 22.56 24.98
30 13.04 15.50 18.42 20.40
50 10.10 12.00 14.27 15.80
125 6.39 7.59 9.02 9.99
250 4.52 5.37 6.38 7.07
500 3.20 3.80 4.51 5.00
1000 2.26 2.68 3.19 3.53
2000 1.60 1.90 2.26 2.50
4000 1.13 1.34 1.60 1.77
B
10 26.09 30.99 36.84 40.79
20 18.45 21.91 26.05 28.85
30 15.06 17.89 21.27 23.55
50 11.67 13.86 16.48 18.24
125 7.38 8.77 10.42 11.54
250 5.22 6.20 7.37 8.16
500 3.69 4.38 5.21 5.77
1000 2.61 3.10 3.68 4.08
2000 1.84 2.19 2.61 2.88
4000 1.30 1.55 1.84 2.04
aSample size is varied from 10 to 4000, when determining the distribution of four variables (for example, glomeruli in stages I to IV) in a poluation. Sample B is the
same as in sample A if histologic classification is reduced to only two stages (for example, “active” versus “chronic” only).
glomerular inflammation that resulted in rapid destruc-
tion and fibrosis of more than 75% of his nephron pop-
ulation. Active injury persists in 20% of the remaining
nephrons, with advanced but incomplete fibrosis present
in 15%. The remaining 5% of nephrons are normal. Thus,
in accordance with the staging proposed in Figure 3, his
nephron profile would be: stage I: 5%, stage II: 5%, stage
III: 15%, and stage IV: 75%. Patient B, on the other hand,
is in a phase of acute active inflammation, with only 10%
completely fibrosed glomeruli (stage IV), 5% partially fi-
brosed (stage III), 80% actively undergoing proliferative
injury (stage II), and the remaining 5% still intact (stage
I).
At present, renal biopsies performed in both cases will
yield information that carries a very high probability of be-
ing completely erroneous regarding the true distribution of
nephron pathology. The reason is the very high statisti-
cal probability that the number of glomeruli sampled by
biopsy (at best 20 to 30) will not reflect the true distribu-
tion of active versus chronic injury in the total nephron
population of both kidneys (Table 2). Human kidneys
contain anywhere from 400,000 to 1.4 million glomeruli,
with marked inter-individual variability [58, 59]. If one
seeks to determine with any degree of confidence the
distribution of four variables (in this case stages I to IV)
in nephron populations above 20,000 to 30,000, then the
following statistical assumptions and formulae apply:
Assumptions: (1) Glomeruli fall randomly into one of
four stages (Fig. 3). (2) Each stage takes on a binomial
distribution (that is, there is some probability that a given
glomerulus is either in, say, stage I, or it is not). (3) There
is mutual exclusivity among the four stages (that is, a
glomerulus in stage I cannot also be in stages, II, III, or
IV). (4) The sum of the probabilities of glomeruli being
in stages I, II, III, and IV equals 100%.
Formulae: Any estimate of the proportion for one stage
(for example, stage I) takes on a margin of error with a
certain degree of confidence. For example, if one samples
250 nephrons and estimates the proportion of glomeruli
in stage I to be 25% based on that sample, one could be
95% confident of a margin of error of 5.37% (Table 2).
This means that had one performed this procedure 100
times, 95 of those times one would be within 5.37% of
the true proportion. Since all the assumptions listed here
hold for patients with glomerulonephritis, one can simply
use the standard method of determining a margin of error
as one would for any binomial problem according to the
following equation:
z of (1 − alpha/2) ×
√
[(p(1 − p)/n)]
where “z of (1-alpha/2)” is the 1-alpha/2 percentile of the
standard normal distribution Z, p is the probability one is
seeking to estimate (such as the proportion of nephrons
in each stage), and n is the sample size. Based on this
equation and assuming equal proportions (P = 0.25) for
each stage (when operating under uncertainty this is the
most unbiased assumption), Table 2 provides margins of
error based on a range of sample sizes and confidence
values. For example sizes less than 30 (most renal biop-
sies contain fewer than 30 glomeruli) it becomes clear
that the margin of error in estimating the proportion of
1914 Nephrology Forum: Filtration function in glomerulonephritis
glomeruli in any particular stage of injury becomes unac-
ceptably high even if one is seeking a confidence limit of
only 90% (Table 2). If one is to obtain a greater than 95%
confidence of being within less than 5% margin of error,
one would need to sample somewhere between 250 and
500 glomeruli!
These calculations should not be surprising, because
it is reasonable to expect that 10 to 20 glomeruli can
hardly be a statistically representative sample for a pop-
ulation of 0.4 to 1.4 million. Lacking this information,
however, all assumptions regarding the success or failure
of therapeutic interventions in altering the course of renal
functional deterioration in glomerulonephritis would
necessarily be faulty. Add to this uncertainty in defining
the true cause of the fall in GFR the relatively low number
of patients in most clinical trials focusing on a particular
form of glomerulonephritis, it is no wonder that the re-
sults of clinical trials are so frequently contradictory and
inconclusive [2] The lack of significant progress in reduc-
ing the overall incidence of glomerulonephritis as a cause
of ESRD [3] therefore might be due in large measure to er-
roneous assumptions regarding the true cause of reduced
GFR in particular patients, such that the response (or lack
thereof) to therapy is rendered open to major errors in
interpretation. For example, if patient A in the hypothet-
ical example given here had been biopsied and, say, 10
glomeruli obtained, the margin of error in estimating ac-
tivity versus chronicity would have been greater than 25%
(Table 2)! If the sample happened to be biased in favor
of activity, and the patient had been treated with aggres-
sive immunosuppressive agents, not only would he have
suffered the toxicity of treatment, but the protocol em-
ployed might have been deemed ineffective in restoring
or preserving GFR in membranoproliferative glomeru-
lonephritis when in fact the major true cause of the fall in
Kf and GFR (partial or total fibrosis in more than 90% of
nephrons) was missed. Conversely, patient B might have
been denied treatment based on its failure in Patient A
or because of a sampling error in the opposite direction.
CONCLUSIONS
The number of patients with glomerulonephritis world-
wide is increasing. Randomized controlled trials have
been difficult to perform and interpret, and the results are
all too often contradictory [2, 54]. Consequently, avail-
able pharmacologic therapies, principally non-specific
immunosuppressive drugs, have made limited impact on
overall disease prevalence and on kidney and patient sur-
vival. It might be time for us to re-assess classifications
and paradigms that have formed the basis of our cur-
rent clinical approaches to this group of diseases. It may
prove more useful for preserving glomerular sieving and
filtration function to approach therapeutic strategies (and
hence clinical trials) based on structural determinants of
functional abnormalities (inflammation versus fibrosis)
rather than specific histopathologic disease entities. In
parallel, the determination of predominant mechanisms
of reduced overall filtration rate should employ statisti-
cally valid approaches to nephron profiles that reflect the
true distribution of inflammation versus fibrosis in the
nephron population of the two kidneys. This is a major
challenge, as renal tissue sampling to obtain the required
number of glomeruli for valid statistical analysis (95%
confidence and margins of error of less than 5%) (Table
2) might not be clinically feasible. A more fruitful ap-
proach possibly would be to search for urinary markers
of disease activity (for example, complement proteins)
that are quantitative, easy to measure, and reflect ongoing
inflammatory injury integrated over the entire nephron
population. Hopefully, the challenges presented in this
Forum will lead to rethinking of current strategies for
diagnosing and treating glomerulonephritis, so that the
prevalence of these diseases, and their contribution to
the incidence of end-stage renal disease, will be reduced.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts Uni-
versity School of Medicine, USA): Approximately 40
years ago, Kark, Pirani, and others [60–62] showed that
renal biopsies containing approximately 5–10 glomeruli
were satisfactory for determining the specific histopatho-
logic type of renal disease, so we have relied heavily
since then on the biopsy for categorization and treatment.
What do we substitute for the biopsy to obtain the more
dynamic information you correctly call for?
DR. BADR: The studies you refer to are indeed pio-
neering works that established the usefulness of biopsy
for determining histopathologic subtypes of renal disease.
Interestingly, in the classic 1958 study analyzing the re-
sults of 500 biopsies by Kark et al [60], the majority of
samples contained 5 to 14 glomeruli. I am not calling for
any substitute to the biopsy to define the type of glomeru-
lar disease in a particular patient. As you point out, there
is a need for more dynamic information regarding the
degree to which changes in GFR are reversible. What I
argue here is that, for purely statistical reasons, the num-
ber of nephrons obtained is inadequate for that type of
analysis. The evolving nature of the disease renders single
determinations of “activity” at one point in time of little
value in long-term follow up and management.
DR. HARRINGTON: Specifically, what do we use to clin-
ically measure “Kf”? Also, how do intrarenal inflamma-
tion and intrarenal fibrosis contribute to its reduction?
DR. BADR: If we could measure Kf, which at this time
is not clinically feasible, or if one were to obtain a quan-
titative measure of what Brian Myers calls “glomeru-
lopenia” [14], we would obtain information which is not
dissimilar from that related by serum creatinine. In other
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words, we would measure the degree of impairment of
glomerular function, but that would provide no insight
as to its mechanism. The question remains as to the de-
gree of reversibility; what proportion of the fall in Kf
is due to inflammation versus fibrosis? The problem is
that the contribution of inflammation or fibrosis to the
fall in Kf varies from nephron to nephron, from day to
day, and from patient to patient. This extreme variabil-
ity demands a type of measurement that can be repeated
frequently and that reflects the degree of active inflam-
mation, even as that component of the fall in Kf varies
over time. How to achieve this is the challenge for all of us.
A starting point might be to analyze urinary proteomics
(urinomics) of pooled samples from large numbers of pa-
tients with active glomerular disease, without regard to
histopathologic subtypes, and see whether we can discern
some predictors of subsequent clinical deterioration.
DR. K. L. GUPTA (Postgraduate Institute of Medical
Education and Research, Chandigarh, India): Dr. Badr,
you have shown us very lucidly the role of inflammation
in glomerular injury and consequent renal dysfunction.
Which of the anti-inflammatory/immunosuppressive
drugs would you have preferred to use in this patient who
had membranous glomerulonephritis at presentation?
DR. BADR: At present, no evidence supports changing
our current approach to the treatment of newly discov-
ered membranous nephropathy. The use of any immuno-
suppressive therapy is guided by the extent of functional
impairment and the activity of the urinary sediment. I
believe the majority of physicians would still use cortico-
steroids as the mainstay of initial therapy for this disease.
DR. GUPTA: What is the role of ACE inhibitors and
ARBs in reducing proteinuria and preserving GFR in
membranous nephropathy?
DR. BADR: Clear evidence indicates that angiotensin
antagonism decreases proteinuria in IgA nephropathy
and other forms of inflammatory glomerulonephritis, in-
cluding the use of combined ACE inhibition and angio-
tensin receptor blockade [2, 63]. It would be of interest
to examine the role of ARBs alone in proteinuric disor-
ders, particularly in view of the potential role of podocyte
AT1 receptor activation during some forms of proteinuric
glomerular diseases.
DR. NATHAN LEVIN (Renal Research Institute, New
York, NY, USA): Do you think that the use of physi-
cal approaches, such as comparative measurements of
renal temperature or imaging techniques [for exam-
ple, multislice magnetic resonance images (MRI)] could
provide an integrated assessment to distinguish inflam-
mation from fibrosis?
DR. BADR: I am not aware of any data supporting the
notion that integrated measurements of renal tempera-
ture are useful in assessing the degree of inflammation.
Your second idea, however, in regard to MRI or other
imaging techniques might be applicable. Imaging is one of
those modalities that might identify targets which, for ex-
ample, are present uniquely in inflamed glomeruli. These
are ideas worth exploring.
DR. JAN J. WEENING (Academic Medical Center, Am-
sterdam, The Netherlands): Considering the success of
cytotoxic and immunosuppressive treatment in severe
necrotizing glomerulonephritis, is there not a clear need
for accurate diagnosis and classification of glomerular dis-
ease, as illustrated in this patient with two different types
of glomerulonephritis?
DR. BADR: There is no question that kidney biopsy,
which clearly defines the specific diagnosis of the under-
lying glomerular disease, is of paramount importance in
guiding therapy. There is always the occasional patient
who presents a diagnostic dilemma that can only be re-
solved through a biopsy, and the identification of spe-
cific entities guides therapeutic approaches. The patient
presented here, as you correctly point out, illustrates the
importance of repeated biopsies in identifying transfor-
mation of one disease form to another and necessitating
a different therapeutic strategy. Pathologists must con-
tinue to play a central role in defining and characterizing
glomerular inflammatory diseases; asking them to quanti-
tatively define the mechanisms underlying overall reduc-
tions in GFR from the examination of kidney biopsies
with 10 or 15 glomeruli, however, is not statistically or
biologically valid or feasible.
DR. WEENING: Glomerular perfusion and capillary
pressure are important determinants of glomerular
immune-complex deposition and accumulation, as well
as glomerular permeability to albumin and other plasma
proteins. Lowering blood pressure also affects compen-
satory hyperfiltration in remaining nephrons and protects
the tubulointerstitial compartment [63, 64]. For example,
unilateral renal artery stenosis protects the kidney from
immune complex accumulation in membranous glomeru-
lopathy and lupus [65, 66]. Would therefore aggressive
lowering of blood pressure (for example, to 100/60 mm
Hg) not be a very sensible way of treating the membra-
nous glomerulopathy in this and other patients?
DR. BADR: I am a strong believer in the profound in-
fluence of physical forces on the biology of glomerular
cells. We have published some of the earliest work on
the effects of such forces on mesangial cell structure and
function in vitro [45]. I have referred to the established
effects of sheer stress on podocyte biology. Your sugges-
tion for aggressive blood pressure lowering is indeed a
reasonable one, and it already enjoys support from the
data on proteinuria.
DR. MAHBOOB LESSAN-PEZESHKI (Tehran Univer-
sity of Medical Science, Tehran, Iran): What are the ba-
sic mechanisms of isolated hematuria in some forms
of immune-mediated glomerulonephritis such as IgA
nephropathy? It seems that if the size of pores in the
membrane is large enough to allow passage of cells (such
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as red blood cells), why can’t proteins, which are much
smaller, pass?
DR. BADR: It is important to recognize that the “pores”
I referred to in relation to the passage of proteins are not
actual physical pores. Rather, they are theoretical con-
structs that fit experimental data supporting the presence
of a “shunt” pathway in the glomerular filtration barrier.
This “shunt” pathway selectively increases the propor-
tion of the filtrate passing through large molecular size
pathways or “pores.” The passage of red blood cells from
the glomerular capillary to the intratubular lumen relates
to the elevated pressures in the capillary and consequent
forced entry of the red cells through the GBM, and leads
to red cell membrane tears and dysmorphic morphology
of red cells, a criterion that has been used to distinguish
glomerular hematuria on examination of the sediment.
This passage occurs at discrete sites and does not repre-
sent a generalized leakiness of the GBM. It might occur
even in the absence of significant proteinuria, as in some
patients with IgA nephropathy.
DR. SALIM MUJAIS (Baxter Healthcare Corporation,
Mc Gaw Park, IL, USA): You suggested that the change
in our therapeutic paradigm requires a “summation pro-
file” that is developed from urinomics. There are prece-
dents of using a “summation response” in nephrology to
guide therapy, such as the “captopril test,” or modified
positron emission tomography (PET) [67]. Considering
the expected long time gap in satisfying the urinomic re-
quirement, do you think there would be value in devel-
oping a clinical test, such as the response to the Merck
product (MK591) that you used in your Kidney Inter-
national paper [51]? Such a test would be non-invasive,
widely applicable, and could be repeatedly applied in the
same patient as either a natural history map or a measure
of therapeutic response.
DR. BADR: That would certainly be a welcome tool,
if it were available. The Merck product, which is a 5-
lipoxygenase activating protein antagonist, did indeed
provide a nearly uniform reduction in urinary protein ex-
cretion rates when given for 4 days, even though the mag-
nitude of the fall in proteinuria was much more evident in
patients with significantly elevated baseline values [51].
Whether MK591 can be used as a “clinical summation
response” test to determine the potential reversibility of
functional derangements remains to be seen. Your idea,
however, is exactly the kind of approach we should be
exploring: clinical measurements that can distinguish pa-
tients likely to benefit from aggressive immunosuppres-
sive or other therapies.
DR. PAULOSE P. THOMAS (Belhoul Specialty Hospi-
tal, Dubai, United Arab Emirates): You mentioned that
you would wait until the GFR dropped before you would
treat a patient who had membranous nephropathy with
immunosuppression (which is the current recommenda-
tion). Don’t you think that by the time the GFR dropped
in a slow and steady manner fibrosis already would have
set in and it might be too late to treat the patient?
The reason why many patients, including the patient
just discussed, did not achieve remission might be be-
cause we lost an opportunity to treat the patient when
his condition was in inflammatory mode and possibly
reversible.
DR. BADR: That is exactly the point of my presenta-
tion. If we had a better way of monitoring the course of
this patient in a manner that would allow us to predict
reductions in GFR before the creatinine has risen, then
it might be possible to initiate treatment in a rational and
timely manner prior to significant increases in serum crea-
tinine. This can only be achieved, however, by monitoring
urinary or other parameters that track, in a dynamic and
faithful manner, ongoing reversible reductions in GFR.
DR. RAJESH RAJ (Welcare Hospital, Dubai, United
Arab Emirates): What is the role of inflammation within
the kidney in patients with essential hypertension, pro-
teinuria, and diminished renal function? Are there stud-
ies on this?
DR. BADR: The role of inflammation in hypertension-
associated glomerular sclerosis is gaining increasing at-
tention. Earlier in this meeting, Dr. Weening presented
elegant formulations linking glomerular sclerosis in pa-
tients with metabolic syndrome and atherosclerosis to
a common underlying systemic inflammatory condition.
Evidence that atherosclerosis is an inflammatory con-
dition is now widely accepted, and the possibility that
some forms of focal segmental sclerosis are the glomeru-
lar counterpart of atherosclerotic vascular injury deserves
further investigation.
PROF. JAMAL ALWAKEL (King Saud University,
Riyadh, Saudi Arabia): What is the role of renal tubule
and interstitial tissue injury in glomerular disease? Could
treatment failures in glomerulonephritis be due to a lack
of attention to factors related to tubular and interstitial
tissue?
DR. BADR: There is no doubt that the degree of inter-
stitial injury is a determinant of clinical outcome in pa-
tients with primary glomerular disease. Recent evidence
points to a potential role for misdirected filtration outside
Bowman’s space leading to initiation of periglomerular
injury and fibrosis [2, 11, 12]. Other mechanisms initiat-
ing tubular injury during glomerulonephritis include fil-
tration of proteins, such as IgG and oxidized low-density
lipoprotein (LDL), which interact with brush border and
other luminal cell surface target molecules, and lead to
the initiation of secondary tubulointerstitial injury [2].
These processes accelerate and amplify loss of nephron
structure and lead to progressive loss of function, but the
primary pathology remains in the glomerulus, and that is
the logical target for therapy.
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DR. JOHN DIRKS (University of Toronto, Toronto,
Canada): In your model, what schematic diagram would
you employ to depict the course of the presented patient
dividing progressive loss of GFR as due to the element of
inflammation, or due to fibrosis or both to illustrate your
thesis?
DR. BADR: As Figure 3 shows, a family of curves de-
scribes the possible course of renal functional deteriora-
tion in patients with glomerulonephritis. For each curve,
the relative contribution of inflammation versus fibrosis
would differ, but it is possible for patients to move from
one curve to another with the intervention of effective
therapy. I believe this model best describes the course of
this patient.
DR. DIRKS: The patient had a slowly progressive
chronic kidney disease, perhaps slowed by rigorous im-
munosuppressive treatment, and then developed a very
inflammatory anti-GBM disease. What factors in mem-
branous glomerulonephritis could make it more suscep-
tible to anti-GBM disease?
DR. BADR: A certain percentage of patients with mem-
branous nephropathy develop anti-GBM disease which,
if not recognized, can lead to rapid irreversible loss
of renal function. The prolonged course of this patient
suggests that the duration of disease might be a fac-
tor predisposing to this ominous complication. The fre-
quency of this occurrence is low, however, and no reli-
able predictive parameters for its development have been
identified.
DR. AIDA MOUSALLI (Saint Joseph University, Beirut,
Lebanon): Is there any place in the therapy of glomeru-
lonephritis for statins and eicosapentaenoic acids? They
are anti-inflammatory agents and have few secondary ef-
fects.
DR. BADR: It would seem reasonable to test the role
of these molecules in inflammatory glomerulonephritis.
As you know, fish oils have given encouraging results in
IgA nephropathy [2]. Statins possess anti-inflammatory
properties and also might be of benefit. I do not know
of any randomized controlled trials using these agents in
glomerulonephritis.
DR. BEENA UNNIKRISHNAN (Cosmopolitan Hospital,
Trivandrum, India): What is the rationale behind the Pon-
ticelli regimen? Why was it used twice for this patient?
DR. BADR: The Ponticelli protocol was designed to
combine steroid-based therapy with immunosuppressive
agents so as to reduce the doses of both [1]. Its use twice
in this patient reflects the choice of his treating physicians
at the time and is not based on the results of controlled
trials demonstrating efficacy. It does illustrate, however,
the lack of clear guidelines in the treatment of this as well
as other primary glomerulopathies.
DR. UNNIKRISHNAN: Would you suggest a blanket
therapy for all patients with glomerulonephritis using
statins, antioxidants, and omega fatty acids?
DR. BADR: I do not think such an approach, reasonable
at it sounds, can be justified at this time. It awaits the
results of randomized controlled studies.
DR. SAMIR H. AL-MAILO (King Fahd Hospital of the
University, Alkhobar, Saudi Arabia): In patients with
acute glomerulonephritis, the outcome can range from
complete resolution to progressive scarring and end-stage
renal disease. In your opinion, what factors determine the
outcome of acute glomerulonephritis?
DR. BADR: The determinants of the outcome of in-
flammatory injury (resolution versus progression) are
the subject of much research and controversy. As you
know, children with post-infectious glomerulonephritis
nearly always recover completely, whereas adults with
the identical disorder often progress due to unrelenting
inflammatory injury [2]. In some way, age modifies our
capacity to put a stop to unwanted auto-destructive in-
flammation. “Stop” signals to inflammation have been
linked through the work of Serhan and his colleagues to
endogenous lipid-based mediators [see 68 and 69 for com-
prehensive reviews of “endogenous anti-inflammation”].
Prominent among these pathways is the 15-lipoxygenase
(15-LOX) enzyme [70], which is induced in macrophages
of nephritic glomeruli in experimental animals [71] and
catalyzes the transformation of arachidonic acid to lipox-
ins and other anti-inflammatory lipids. Introduction of the
human 15-LOX gene into rat kidneys also ameliorates
glomerular immune injury [72]. The capacity to mount
a robust anti-inflammatory response is in turn geneti-
cally determined and linked, in part, to interleukin-4 and
13 (IL-4 and IL-13) synthesis by Th2-lymphocytes [71,
73, 74]. IL-4 and IL-13 are uniquely capable of induc-
ing de-novo expression of 15-LOX in human leukocytes
[73]. There is thus evidence supporting the notion that
the extent of induction of endogenous anti-inflammatory
responses dictates the outcome of glomerular immune
injury [68–74]. Clinically, predictors of a poor outcome
are the severity of the reduction in GFR on diagnosis,
and the magnitude of proteinuria [2].
DR. HARRINGTON: What urinary biomarkers could be
used at present, and what is the “gold standard” to which
we would compare these newer more dynamic markers?
DR. BADR: Currently there are no reliable urinary
markers for ongoing renal inflammation. The National
Institutes of Health has expressed interest in this issue,
and a recent workshop was dedicated, in part, to devel-
oping the science of urinomics in the setting of glomeru-
lonephritis. The nephrology community will eagerly
anticipate the results and recommendations of this work-
shop as well as future conferences and research efforts to
help identify urinary markers that provide an integrated
measurement of active inflammation in glomeruli.
DR. WEENING: Several centers currently study re-
nal biopsies by gene transcription and proteomics anal-
ysis in addition to classical histopathology, including
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immunofluorescence and electron microscopy. The out-
come of renal tissue RNA, proteomics, and in situ hy-
bridization in relation to histopathology as well as urine
and plasma genomics and proteomics might yield inter-
esting new data and could change the contribution of
plasma, urine, and biopsy data to the diagnosis.
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